EISAI PRESENTS LATEST PHASE I/II DATA ON IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011　RESULTS SUGGEST SAFETY, TOLERABILITY AS WELL AS CLINICAL ACTIVITYIN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE | Investors（2016） | EA Pharma Co., Ltd.

Written by EAファーマ | Jun 13, 2016 2:26:00 AM

Eisai Co., Ltd. (“Eisai”) put out today the following press release about E6011, which Eisai has developed jointly with its gastrointestinal area subsidiary EA Pharma Co., Ltd.

EISAI PRESENTS LATEST PHASE I/II DATA ON
IN-HOUSE DEVELOPED ANTI-FRACTALKINE
ANTIBODY E6011
RESULTS SUGGEST SAFETY, TOLERABILITY AS
WELL AS CLINICAL ACTIVITY
IN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE

For full text of the press release, please see the URL below in the website of Eisai Co., Ltd.
http://www.eisai.com/news/news201640.html

EA pharma Co., Ltd.
Corporate Planning Dept.

View full post

EISAI PRESENTS LATEST PHASE I/II DATA ON IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011 RESULTS SUGGEST SAFETY, TOLERABILITY AS WELL AS CLINICAL ACTIVITYIN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE | Investors（2016） | EA Pharma Co., Ltd.

EISAI PRESENTS LATEST PHASE I/II DATA ON IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011　RESULTS SUGGEST SAFETY, TOLERABILITY AS WELL AS CLINICAL ACTIVITYIN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE | Investors（2016） | EA Pharma Co., Ltd.